Adverum Biotechnologies Company
Adverum Biotechnologies developed delivery systems and gene therapy. ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. ADVM-022 (AAV.7m8-aflibercept) is administered as a single, in-office intravitreal (IVT) injection, designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF injections, and improve vision outcomes for patients with wet age-related macular degeneration (wet AMD).
Connections from
Estimated Revenue:
Less than $1M
Funding Status:
Post-IPO Equity
Industry:
Gene Therapy, Gene therapy
Investors Number:
6
Last Funding Date:
2006
Number Of Exists:
101-250
Technology:
Others
Founded Date:
2006
Headquarters:
Menlo Park, California, United States
Total Funding:
$70.7M
Last Funding Type:
Post-IPO Equity